Promising New Breakthrough in Breast Cancer Research

　　Promising New Breakthrough in Breast Cancer Research , Promising New Breakthrough in Breast Cancer Research . Promising breakthrough in breast cancer research Promising breakthrough in breast cancer research The combination of two new drugs killed 75 percent of mouse breast cancer cells and inhibited tumor recurrence, according to researchers at the Massey Cancer Center at the University of Virginia-Commonwealth.　　Dr. Paul Dent led the study, which was published online Nov. 14 in Cancer Biology and Therapy. They took the results of a successful 2002 study in the laboratory and validated them in animal studies. In this study, the researchers analyzed the combined effects of two novel drugs – UCN-1 and MEK1/2 inhibitors – that inhibit a number of protein kinases that play a role in tumor survival signaling pathways.　　”Both drugs, in addition to being effective in inhibiting tumor cell and tumor growth, are less toxic to non-tumor cells,” Dent said. “We hope to apply these exciting findings to humans.” When the two drugs were studied separately, they killed only a small number of cells, while the combined results were exceptionally impressive. “After five days of application, we found massive tumor cell death,” Dent said. “Three researchers conducted the same study separately and independently, and all got the same results.”